This is the authors' abstract. We don't add key points for this paper.
Gastro intestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastro intestinal tract [1] and account for 80 % of all GI tumors. Approximately 30% of GISTs are malignant [2]. Occurring throughout the entirety of the GI tract, GISTs most commonly present in the stomach or small intestine [3], Most GISTs present asymptomatically. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C- Kit). For localized, resectable tumors, surgical resection remains the cornerstone of treatment. For patients with locally advanced disease, preoperative imatinib can be used to help reduce tumor burden before resection [4]. We report the case of a 48 years old patient who presented a gastric stromal tumor invading the spleen, the pancreas and a portion of the left liver. After 6 months of néo adjuvant Imatinib therapy, the patient has undergone a longitudinal gastrectomy associated with splenectomy caudal pancreatectomy and left hepatectomy in which the evolution was favorable.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: